Mr. Gadi Levin reports

VAXIL ANNOUNCES CLOSE OF PREVIOUSLY ANNOUNCED NON-BROKERED PRIVATE PLACEMENT AND UPDATE ON BOARD OF DIRECTORS

Vaxil Bio Ltd. has completed its previously announced non-brokered private placement (see press release dated Nov. 24, 2025) for gross proceeds of $140,000. Investors in the private placement subscribed for 1,244,441 units at a price of 11.25 cents per unit. Each unit consisted of one common share in the capital of the company and one common share purchase warrant, with each warrant being exercisable, at any time prior to Dec. 2, 2030, to acquire one additional common share at an exercise price of 15 cents per warrant share.

In accordance with applicable Canadian securities law, the securities issued pursuant to the private placement are subject to a four-month-and-one-day hold period expiring on April 3, 2026. Additionally, in connection with the private placement, Vaxil compensated certain finders by payment of finders' fees in the aggregate amount of $11,200 and the issuance of an aggregate of 99,555 finder warrants. The finder warrants have identical terms to those of the warrants.

Net proceeds from the private placement are presently expected to be used to continue to actively explore other strategic options beyond the health care sector for maximizing shareholder value.

The company announces that Ari Kellen and Shawn Langer have resigned from the company's board of directors, effective immediately. Also effective immediately, the company announces the appointment of Simon Igelman to the company's board.

Mr. Igelman is a corporate transactional lawyer. His practice focuses on corporate finance and mergers and acquisitions as well as providing advice on structured finance and capital markets mandates. Mr. Igelman has represented private and public companies on a variety of transactions, including private placements of equity and debt securities, securitizations in a variety of asset classes, public and private acquisitions, and general corporate and commercial law matters.

"On behalf of the board of directors of Vaxil, I would like to thank Mr. Kellen and Mr. Langer for their invaluable contributions during their tenure as directors of the company. We appreciate their dedication and service, and we wish them every success in their future endeavours," said Gadi Levin, chairman of Vaxil. He continued, "We are pleased to welcome Mr. Igelman to the board and look forward to working with him as we pursue new strategic opportunities for the benefit of our shareholders."

About Vaxil Bio Ltd.

Vaxil was an immunotherapy biotech company focused on targeting prominent cancer markers and infectious diseases. Its lead product was ImMucin, for which it had received orphan drug status from the FDA (U.S. Food and Drug Administration) and EMA (European Medicines Agency). The company is presently evaluating the pursuit other business, which may or may not be in the biotechnology industry, in order to enhance shareholder value.

We seek Safe Harbor.